Meeting Report on the Second Targeted Tumor Therapies

This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor Therapies and held from April 1–3, 2009 in Berlin, Germany. The meeting focused on noncarrier-based targeted tumor therapies and their clinical application. The world's leading experts in this field presented the state of the art on tumor-specific targeting and tumor growth inhibition, drug design and production, and the description of innovative strategies for improved delivery. The topics concentrated on immunotoxins and other targeted toxins as anticancer drugs, thus providing a specialized meeting platform not existing elsewhere for these therapeutics. Although a number of innovative approaches on the avoidance of immune responses against highly effective toxins were presented, a notable conclusion of the meeting and direction for future research is the acute need to further reduce the immunogenicity of the targeted toxins, which hampers the efficacy of this group of therapeutics in clinical studies. The meeting successfully fostered plans for further research and cooperation between different groups to hopefully achieve advanced translational and clinical studies. Mol Cancer Ther; 9(1); 17–23

[1]  A. Plückthun,et al.  EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins , 2009, Molecular Cancer Therapeutics.

[2]  W. Cho Cancer research on non-small cell lung cancer in smokers and non-smokers: snapshots from the AACR annual meeting 2009 , 2009, Cancer biology & therapy.

[3]  W. Cho Updates in cancer research: insights from the AACR 100th Annual Meeting , 2009, Expert review of molecular diagnostics.

[4]  S. Howell,et al.  Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors , 2009, Molecular Cancer Therapeutics.

[5]  D. Thompson,et al.  Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide , 2009, Molecular Cancer Therapeutics.

[6]  W. Wels,et al.  Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor , 2009, Molecular Cancer Therapeutics.

[7]  U. Kompella,et al.  Luteinizing hormone-releasing hormone receptor–targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy , 2009, Molecular Cancer Therapeutics.

[8]  Qing X. Yang,et al.  Efficacy of interleukin-13 receptor–targeted liposomal doxorubicin in the intracranial brain tumor model , 2009, Molecular Cancer Therapeutics.

[9]  H. Fuchs,et al.  Targeted tumor therapies at a glance. , 2009, Current drug targets.

[10]  G. Prendergast Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .

[11]  Gert Daniel Biotechnologie , 1982 .

[12]  J. A. del Regato,et al.  Therapeutic radiology. , 1980, JAMA.